The menopause consultation is an opportunity to look beyond hot flashes. In their 2020 clinical review, Santen and colleagues place cardiovascular assessment alongside symptom relief, breast health and fracture prevention. Their central idea is personalized care: the same treatment can have a different balance of benefits and harms in people with different underlying risks.
Start with your underlying risk
A cardiovascular review considers blood pressure, cholesterol, diabetes, smoking, age, family history and any previous heart or vascular disease. These factors matter whether or not you are considering hormone therapy. Knowing your starting point makes a discussion about treatment more meaningful than asking whether hormones are simply “safe” or “unsafe”.
The 2020 paper illustrates the use of a cardiovascular risk calculator to estimate the likelihood of an event over a defined period. Such a score is an estimate for a population of similar people, not a prediction of what will happen to you. The calculator, thresholds and recommendations used in that paper reflect its publication date; your clinician should use tools and guidance appropriate to today’s practice and your country.
- Bring recent blood-pressure and cholesterol results if you have them.
- Mention diabetes, smoking, migraine, blood clots and any previous stroke or heart disease.
- Ask which risk factors you can change and how they will be followed over time.
Why timing enters the hormone discussion
Age and time since menopause influence the benefit–risk conversation about systemic menopausal hormone therapy. Starting treatment near menopause is not the same clinical situation as starting it much later, when underlying vascular disease may be more common. The review describes this distinction rather than treating all postmenopausal women as one group.
Timing is only one part of the assessment. Being younger than 60 or within 10 years of menopause does not erase a history of stroke, a clotting disorder or other contraindications. Conversely, a calendar date alone cannot replace a discussion of symptoms, medical history and alternatives.
Oral and transdermal treatment are not identical
Estrogen taken by mouth passes through the liver before reaching the wider circulation. Transdermal estrogen, delivered through the skin, avoids this first-pass route. The paper explains why route may matter in someone with particular cardiovascular or clotting concerns.
The authors also emphasize the limits of the evidence: many comparisons between oral and transdermal treatment come from observational studies, not large randomized trials of every formulation. A possible advantage for one outcome is not a guarantee that a treatment is risk-free. Route, dose, progestogen needs and your personal history belong in the same conversation.
Keep prevention on its own track
The review highlights smoking cessation, regular physical activity and attention to weight and metabolic health as part of comprehensive care. Blood-pressure control, diabetes care and lipid management may require their own treatment plan. Symptom improvement does not substitute for these preventive measures.
At your next visit, ask two separate questions: “What will help my menopausal symptoms?” and “What is my plan for long-term heart health?” Separating the goals makes it easier to understand what each intervention is intended to do.